Entain (ENT), the global sports betting and gaming group, today reported Interim Results1 for the six-month period ended 30 June 2025. H1 ahead of expectations with accelerating strategic progress; FY25 guidance
Entain (ENT), the global sports betting and gaming group, today reported Interim Results1 for the six-month period ended 30 June 2025. H1 ahead of expectations with accelerating strategic progress; FY25 guidance
The junior market displayed less optimism, as evidenced by the AIM All-Share Index dropping 0.7% to 734 by Friday’s end of the week. Similarly, the blue-chip stocks experienced a downturn,
Lift Global Ventures (AQSE:LFT), an investment company focused on financial media, technology and the energy sector, announced that one of its investment portfolio companies, Trans-Africa Energy Limited, has secured conditional equity
The FTSE 100 ended the week with a 1.5% increase. Leading the gains was NatWest, which saw its shares climb 7.09% following the confirmation of its new chief executive. Close
Cambridge, UK, 15 February 2024 – Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces the completion of the single ascending
Pensana (PRE) advised that on 29 August 2023, 30 August 2023 and 31 August 2023, Paul Atherley purchased shares in the company.
Tirupati Graphite (TGR), the specialist graphite producer and developer of sustainable new age materials, announced its Audited Final Results for the year ended 31 March 2023 (FY23).
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
DeepVerge (DVRG) said it notes recent market speculation regarding forthcoming loan repayments and a potential equity fundraising.
i3 Energy (I3E), an independent oil and gas company, announced unaudited results for its period ended 30 June 2022.
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update